TAO Synergies (TAOX) Assets Average (2020 - 2026)
TAO Synergies' (TAOX) quarterly Assets Average came in at $26.1 million in Q2 2026, up 48.49% on a YoY basis from $17.6 million in Q2 2025, and down 8.32% quarter-over-quarter from $28.4 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Assets Average (2020 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Assets Average for 7 consecutive years, with $26.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Assets Average rose 48.49% year-over-year to $26.1 million; the trailing twelve-month figure through Jun 2026 stood at $26.1 million (up 48.49% YoY), and the FY2025 full-year result was $21.8 million, down 10.81% from the prior year.
- Assets Average eased to $26.1 million in Q2 2026 per TAOX's latest filing, from $28.4 million in the prior quarter.
- Across five years, Assets Average topped out at $37.6 million in Q1 2023 and bottomed at $16.5 million in Q1 2025.
- Historically, Assets Average has averaged $27.7 million across 5 years, with a median of $28.7 million in 2022.
- The sharpest annual moves came in 2022 and 2025: Assets Average jumped 193.87% in 2022, then tumbled 45.36% in 2025.
- Over 5 years, Assets Average stood at $33.0 million in 2022, then slipped by 3.77% to $31.7 million in 2023, then tumbled by 36.1% to $20.3 million in 2024, then advanced by 8.96% to $22.1 million in 2025, then climbed by 18.0% to $26.1 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $26.1 million, $28.4 million, and $22.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | 5.51 Bn |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - | 26.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.08 Mn |
| Mar 31, 2026 | 28.44 Mn |
| Dec 31, 2025 | 22.10 Mn |
| Sep 30, 2025 | 19.08 Mn |
| Jun 30, 2025 | 17.56 Mn |
| Mar 31, 2025 | 16.53 Mn |
| Dec 31, 2024 | 20.28 Mn |
| Sep 30, 2024 | 25.61 Mn |
| Jun 30, 2024 | 28.89 Mn |
| Mar 31, 2024 | 30.26 Mn |
| Dec 31, 2023 | 31.74 Mn |
| Sep 30, 2023 | 32.90 Mn |
| Jun 30, 2023 | 34.98 Mn |
| Mar 31, 2023 | 37.57 Mn |
| Dec 31, 2022 | 32.98 Mn |
| Sep 30, 2022 | 28.46 Mn |
| Jun 30, 2022 | 30.97 Mn |
| Mar 31, 2022 | 33.94 Mn |
| Dec 31, 2021 | 33.94 Mn |
| Sep 30, 2021 | 32.66 Mn |